Labcorp Holdings Inc. $LH Shares Sold by Massachusetts Financial Services Co. MA

Key Points

• Massachusetts Financial Services trimmed its stake in Labcorp by 4.2%, selling 25,036 shares and now holds 570,075 shares valued at about $143.0 million (≈0.69% of the company).
• Wall Street sentiment is broadly positive with an average target price of $307.20 and more buy/target upgrades recently, though some firms issued neutral/hold views.
• Labcorp beat quarterly EPS estimates ($4.07 vs. $3.95), set FY2026 guidance of 17.55–18.25 EPS, and declared a $0.72 quarterly dividend (annualized $2.88, ~1.1% yield).

Massachusetts Financial Services Co. MA lessened its position in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) by 4.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 570,075 shares of the medical research company's stock after selling 25,036 shares during the period. Massachusetts Financial Services Co. MA owned about 0.69% of Labcorp worth $143,020,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. HBK Sorce Advisory LLC grew its holdings in Labcorp by 4.3% during the 3rd quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company's stock worth $254,000 after acquiring an additional 38 shares in the last quarter. Pure Financial Advisors LLC boosted its holdings in shares of Labcorp by 3.9% in the 3rd quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company's stock valued at $292,000 after buying an additional 38 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of Labcorp by 48.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company's stock valued at $35,000 after buying an additional 40 shares in the last quarter. Burney Co. boosted its holdings in shares of Labcorp by 0.5% in the 3rd quarter. Burney Co. now owns 8,819 shares of the medical research company's stock valued at $2,532,000 after buying an additional 42 shares in the last quarter. Finally, Advisor OS LLC boosted its holdings in shares of Labcorp by 5.4% in the 3rd quarter. Advisor OS LLC now owns 821 shares of the medical research company's stock valued at $236,000 after buying an additional 42 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Wall Street Zen cut shares of Labcorp from a "buy" rating to a "hold" rating in a report on Saturday, April 4th. Weiss Ratings upgraded shares of Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, February 10th. JPMorgan Chase & Co. upped their target price on shares of Labcorp from $319.00 to $330.00 and gave the company an "overweight" rating in a report on Wednesday, February 18th. Piper Sandler upped their target price on shares of Labcorp from $270.00 to $300.00 and gave the company a "neutral" rating in a report on Tuesday, February 24th. Finally, Robert W. Baird upped their target price on shares of Labcorp from $313.00 to $326.00 and gave the company an "outperform" rating in a report on Wednesday, February 18th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $307.20.

Labcorp Stock Up 0.2%

LH stock opened at $261.35 on Monday. The company has a fifty day moving average price of $274.39 and a 200 day moving average price of $268.64. Labcorp Holdings Inc. has a 12 month low of $209.38 and a 12 month high of $293.72. The company has a market cap of $21.54 billion, a price-to-earnings ratio of 24.99, a price-to-earnings-growth ratio of 1.79 and a beta of 1.02. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.42 and a quick ratio of 1.23.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, beating the consensus estimate of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The firm had revenue of $3.52 billion during the quarter, compared to the consensus estimate of $3.56 billion. During the same quarter in the prior year, the firm earned $3.45 EPS. Labcorp's revenue for the quarter was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Sell-side analysts expect that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be given a $0.72 dividend. The ex-dividend date is Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp's dividend payout ratio is 27.53%.

Insider Buying and Selling at Labcorp

In related news, EVP Jonathan C. Meltzer sold 87 shares of the company's stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the completion of the sale, the executive vice president owned 2,782 shares in the company, valued at $807,948.44. This represents a 3.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Brian J. Caveney sold 1,500 shares of the company's stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total transaction of $429,465.00. Following the transaction, the executive vice president owned 30,107 shares of the company's stock, valued at approximately $8,619,935.17. The trade was a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 16,113 shares of company stock worth $4,547,450 in the last 90 days. Company insiders own 0.84% of the company's stock.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.